Unfinished Business: Demonstrating Value In Pharmacogenomic Testing
This article was originally published in The Gray Sheet
Executive Summary
Pharmacogenomic testing and personalized medicine are clearly the wave of the future, but establishing their value to society will be key for their successful adoption, economist Kathryn Phillips, PhD, University of California-San Francisco, maintained at an April 4 symposium sponsored by Johns Hopkins University's Genetics and Public Policy Center
You may also be interested in...
C-Path Institute Exec Targets “Points Of Pain” In Device Development
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products
C-Path Institute Exec Targets “Points Of Pain” In Device Development
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products
Third Wave, Now An IVD Company, Is Banking On Personalized Medicine
Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business